This is a podcast episode discussing Chronic Myeloid Leukemia (CML) and the advancements in Tyrosine Kinase Inhibitor (TKI) therapies for its treatment. It explains that CML is a type of blood cancer caused by an abnormal protein and highlights how earlier TKIs transformed the disease from fatal to manageable. The episode then focuses on new-generation TKIs, like asciminib and ponatinib, detailing their different mechanisms of action, improved efficacy against resistant forms, and better safety profiles compared to previous treatments. The conversation with a medical expert underscores the promising future of personalized medicine in CML treatment.